What is 32Co?
Founded in 2021, 32Co operates at the intersection of telemedicine and clinical collaboration. The company provides a sophisticated digital infrastructure that enables general practitioners to consult with a global network of specialists, effectively democratizing access to high-quality care. By integrating specialist expertise directly into the local clinic environment, 32Co addresses critical inefficiencies in healthcare delivery. This model not only enhances patient outcomes by providing specialized insights at the point of care but also empowers generalist clinicians to expand their service offerings without the traditional barriers of geographic or institutional silos. As a disruptor in the healthcare technology space, 32Co is redefining how medical knowledge is distributed and utilized across the primary care landscape.
How much funding has 32Co raised?
32Co has raised a total of $2.7M across 1 funding round:
Other Financing Round
$2.7M
Other Financing Round (2023): $2.7M with participation from Wavemaker Three-Sixty Health and Balderton
Key Investors in 32Co
Wavemaker Three-Sixty Health
Wavemaker Three-Sixty Health is a leading U.S. venture capital fund that focuses exclusively on early-stage healthcare startups, investing in promising companies across North America to improve patient outcomes and lower costs.
Balderton
Balderton Capital is a London-based venture capital firm that raises dedicated funds to invest in early-stage, high-growth technology companies across Europe, typically leading Seed and Series A rounds.
What's next for 32Co?
With this major strategic investment, 32Co is well-positioned to scale its operations and deepen its market penetration. The company's roadmap likely involves expanding its network of specialist clinicians and enhancing its platform's interoperability with existing electronic health record systems. By focusing on operational efficiency and clinical integration, 32Co aims to solidify its role as an essential utility for modern healthcare providers. The infusion of capital will be instrumental in supporting the firm's growth trajectory as it seeks to standardize collaborative care models across international markets, ultimately driving down costs while improving the quality of patient-centered medical services.
See full 32Co company page
